17.10.2014 • NewsAlexander WesselsArchromaBASF

BASF Selling Textile Chemicals Business to Archroma

BASF is selling its textile chemicals business for an undisclosed sum to Archroma, a Reinach, Switzerland-based company owned by private equity investor SK Capital Partners.

Still to be approved by antitrust authorities, the transaction is set to close in the first quarter of 2015. It comprises, alongside BASF's global textile chemicals business, the assets of the German group's Karachi-based subsidiary BASF Pakistan.

The BASF business, which will be integrated into Archroma's Textile Chemicals Specialties Unit, employs 290 people, including 230 in Asia.

Selling the activities will sharpen the focus of the German group's Performance Chemicals division on growth-driven customer industries, BASF said.

In a very competitive and highly fragmented market, division head Hans W. Reiners, said BASF has positioned the textile chemicals business as one of the leading global suppliers.

Ongoing consolidation in the market means that critical mass is needed to grow the business successfully, Reiners said, adding that he sees positive future growth perspectives for textile chemicals under Archroma's umbrella.

The Swiss firm is in the process of building a specialty chemicals business from assets flogged off by leading European and American chemical producers, including Clariant and most recently Chemtura. In May of this year, Archroma also acquired 49% of textile manufacturer M. Dohmen.

In the latest deal, "we are bringing together the century-old history of BASF textile chemicals products, technologies and people with Archroma's already strong heritage from Hoechst, Sandoz and Clariant," said the company's CEO, Alexander Wessels.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read